ReviewJournal of cancer prevention2026

From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology.

Zhibin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.